Northern Territory’s patients get improved access to advanced medical imaging tech

Healthcare IT News | March 07, 2019

Royal Darwin Hospital (RDH) and Siemens Healthineers have partnered in a venture to expand oncology services available in the Northern Territory, providing the hospital with an advanced PET CT scanner that offers patients the capability to scan faster using lower doses of radiation and personalises scans to a patient’s specific medical condition. RDH is the largest hospital in the Northern Territory region of Australia. Siemens Healthineers A/NZ Molecular Imaging Business Manager Tim Lagana said that the Biograph mCT Flow Edge scanner features advanced capabilities such as improved lesion detectability and reduces unnecessary exposure to radiation with two features.  The first is FlowMotion, which eliminates the need for bed-based imaging used by traditional PET scanning forms.

Spotlight

Rhode Island Hospital Honors Lifetime Champion Michael G. Ehrlich, MD at the 2015 President’s Pursuit of Excellence Dinner held on Wednesday, November 18, 2015. http://giving.lifespan.org/PPOE-2015


Other News
HEALTH TECHNOLOGY

Philips and IJsselland Hospital sign long-term technology partnership

Royal Philips | December 24, 2021

Royal Philips, a global leader in health technology, today announced it has signed a 12-year strategic partnership with IJsselland Hospital (Capelle aan den Ijssel, The Netherlands). As the hospital’s strategic technology partner, Philips will target improved care for patients and care providers at IJsselland Hospital and in the surrounding region. The collaboration will focus on innovation, digitalization and optimization, and includes the purchase of patient monitoring and radiology solutions including CT and MRI systems. Home monitoring collaboration expanded In addition to the new strategic partnership, Philips and IJsselland Hospital plan to expand their existing home monitoring partnership for patients with heart failure and COPD. Philips will provide clinical and patient decision support software which enables implementation of remote health and care programs and facilitates collaboration between different healthcare providers. “Technological developments in healthcare are currently moving very fast,” said Albert van Wijk, Chairman of IJsselland Hospital’s Board of Directors. “As a regional hospital, we want to keep up with these developments to provide the best care for our patients. We have chosen Philips as a technology partner to jointly develop the hospital of the future. This will be good for our patients and our healthcare professionals. Moreover, Philips’ vision fits well with our strategy.” “Over the past year, we have worked with IJsselland Hospital to convert their strategy and challenges into a partnership. I am very proud of this partnership, in which we don’t focus solely on technology but look more broadly at the challenges the hospital faces. A great deal of attention is paid to innovation, which is why we are starting a joint fund for innovation and optimization. We also want to work explicitly on optimizing care processes, so that the hospital can work smarter and save costs.” Léon Kempeneers, Health Systems, Philips Benelux About Royal Philips Royal Philipsis a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 78,000 employees with sales and services in more than 100 countries.

Read More

FUTURE OF HEALTHCARE

Althea Expands Its Growing Broadband Coverage Area to Tacoma WA

Althea | March 26, 2022

Althea is proud to announce Tacoma, WA is the latest addition to its growing broadband coverage area, with installations and infrastructure investment focused in the Hilltop neighborhood. Founded in 2017, Althea’s mission is rooted in the belief that affordable broadband connectivity is a fundamental right for all people that strengthens communities, economic growth, educational opportunities, and healthcare access. Althea is a distributed Internet Service Provider which works together with local communities and network operators to provide sustainable high speed and low cost broadband access. This is made possible by Althea’s unique technology, infrastructure, and routing protocol. Althea’s routing protocol allows the service and accounting layers of the ISP to be almost entirely automated, and maximizes bandwidth utilization (i.e. delivers lower latency and higher speeds than one would typically experience from a given network connection, when compared to a traditional ISP routing protocol). This technology negates the need for contracts, late fees, and other drawbacks of traditional internet delivery. The mesh topology used to connect users also allows individuals to host infrastructure themselves, growing the network, and earning revenue share for doing so. This keeps value in the community, encourages community involvement, maintains low costs, and creates an ever more resilient network architecture. Althea uses a unique pay-as-you-go payment model, making it easy for users to manage costs. Additionally, each user has access to the always-on free tier, guaranteeing they will have access to no-cost basic internet, regardless of their financial situation. Unlike traditional ISPs, Althea’s technology does not artificially throttle bandwidth or utilize speed tiers either, so users always get the maximum speed their equipment is capable of delivering. Althea users in Tacoma can expect speeds around 100 Mbps and pay, on average, around $25/month. “Many people don’t have access to the internet, not because of availability, but costs and other barriers keep them from this vital resource.We believe internet access is a human right, which is why we provide an always-on, free tier of internet.” Deborah Simpier, Althea CEO and co-founder Hilltop, Tacoma was also one of the first proof-of-concept networks for Althea, partnering in 2020 with Tacoma Cooperative Network and the University of Washington to build and test community led LTE networks. Through this work in Open5GS, Althea developed KeyLTE, which is an embedded EPC inside an Althea home router, which provides flexibility to build and grow LTE/5G networks anywhere, quickly and affordably.

Read More

MEDICAL DEVICES

MedTech Company STENTiT Raises €1.8 million in Seed Round

STENTiT | April 25, 2022

STENTiT, a medical device company bringing a novel class of regenerative endovascular implants for the treatment of cardiovascular diseases, has closed a €1.8 million seed investment round. The funding facilitates further pre-clinical development and batch production of a regenerative stent (see video) for peripheral indications. The investment was made by Dutch investors NextGen Ventures, Brabant Development Agency and the Ten Cate Investment Company. STENTiT is an emerging player in the field of regenerative medical devices, offering a breakthrough solution for cardiovascular interventions by developing first-of-its-kind endovascular implants with regenerative capacity. Using a catheter-based approach, these devices provide the ability to restore arteries without the need for an invasive surgical intervention. The aim is to ultimately restore the affected blood vessel from the inside out to provide a lifelong solution. As a first target indication, the company wants to improve the treatment of critical limb ischemia. This progressive form of peripheral artery disease affects almost 5 million people in the EU and the US in which the blood flow to the foot is severely being compromised. Unfortunately, current treatment options are ineffective, resulting in amputation within 6 months in 40% of these patients. With the regenerative stent, blood flow to the foot will be maintained by securing vascular patency using temporary mechanical support and improving long-term efficacy by inducing vascular repair, thereby preventing thousands of amputations each year. "We are excited to receive the support of these esteemed Dutch early-stage investors. This financing round validates our vision to bring a novel class of implants that can rebuild the affected blood vessels. We are looking forward taking the next steps getting our regenerative stents ready for clinical trials. With our first product, we aim to treat millions of patients suffering from peripheral artery diseases, and save their limbs from amputation." Bart Sanders, CEO of STENTiT About STENTiT STENTiT is a medical device spin-off company from the Dutch Eindhoven University of Technology, focusing on the development of regenerative endovascular implants. These bioresorbable devices trigger a natural healing response by the circulating blood cells, in which the implant is being replaced by new vascular tissue to restore the artery from the inside-out. Since the establishment of the company, STENTiT has received broad international recognition and awards for its high-potential approach, covering world leading stages. As the company is currently going through the next translational phases, STENTiT is on its way to fulfill its ambition to become the new standard in endovascular treatment, providing a life-changing solution for millions of cardiovascular patients around the world.

Read More

DIGITAL HEALTHCARE

Purpose Investments Announces Launch of Purpose Healthcare Innovation Yield ETF, Canada’s First Fund to Focus on Innovation in Biotech and Healthcare

Purpose Investments | January 19, 2022

Purpose Investments Inc. (“Purpose Investments” or “Purpose”) is pleased to announce the launch of Purpose Healthcare Innovation Yield ETF (the “Fund”). The Fund has closed the offering of its initial units, and units of the Fund will begin trading today on the Toronto Stock Exchange under the ticker, HEAL. The Fund is the first of its kind in Canada to provide actively managed exposure to innovation leaders in biotech and healthcare. The recent advances in healthcare are only the beginning of what Purpose believes to be a new multi-year cycle in biotech and healthcare breakthroughs that will provide investors with opportunity for attractive long-term returns. The Fund will invest in an all-cap portfolio in the high-growth areas of gene-editing, digital healthcare, medical testing, dental, health maintenance, hospitals, pharmacies, and animal health. The portfolio holdings are primed for long-term growth and armed with commercialization opportunities and a strong pipeline of products under development. The Fund will also employ a covered call options strategy to generate additional yield and will have a more attractive income profile than the broad healthcare index. “The past two years have shown just how important it is to have innovative companies develop vaccines and push forward medical advancements. Between the pandemic and our aging population, the spotlight is on the industry to really grow and innovate. We launched this Fund to give Canadians an opportunity to get actively managed exposure to the healthcare companies that are changing the world with cutting-edge medical and technological advancements.” Som Seif, founder and CEO of Purpose Investments Purpose is the manager of the Fund and Next Edge Capital Corp. (“Next Edge Capital”) will act as the Fund’s sub-advisor. The Fund will be actively managed by Eden Rahimof Next Edge Capital, one of the world’s leading experts in healthcare investing. Mr. Rahim has an academic background in molecular genetics and extensive experience managing life-science and biotech portfolios. His active management, informed by his science background and industry experience, will position the Fund to capitalize on high-growth opportunities in the biotech and healthcare sectors. “With this Fund, we will work to strategically identify key healthcare companies developing innovations that will profoundly improve people’s lives,” says Rahim. “Purpose Healthcare Innovation Yield ETF aims to provide investors with exposure to unique opportunities that may not be on their radar, so they can reap the full rewards of the high-growth areas in healthcare and science.” “Eden is one of the leading global experts in healthcare investing, and someone who understands the math as well as the science backing the portfolio. We are excited to have such a seasoned portfolio manager help us maximize the growth opportunities in the space and provide investors with a strategy to generate attractive yield,” Seif concluded. About Purpose Investments Purpose Investments Inc. is an asset management company with approximately $14 billion in assets under management. Purpose has an unrelenting focus on client-centric innovation, and offers a range of outcome-focused products. Purpose Investments is led by well-known entrepreneur Som Seif and is a division of Purpose Financial, an independent technology-driven financial services company.

Read More